Cancer Family
Hepatobiliary Neoplasm
CI-CAN-00000198Explore in graph →
Non-malignant1,187 active trials17 approved drugs42 evidence items
- NCIt
- C8614
Loading cancer entity…
Cancer Family
CI-CAN-00000198Explore in graph →
Clinical trials
5,262 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06535737 | A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab(CPAB) | not yet recruiting | Phase 2 | 40 | Chulalongkorn UniversityOTHER | 0 | Aug 2, 2024 | clinicaltrials |
| NCT06530823 | Pemigatinib Combined With Durvalumab for Previously Treated Biliary Tract Carcinoma | not yet recruiting | Phase 2 | 38 | Eastern Hepatobiliary Surgery HospitalOTHER | 0 | Jul 31, 2024 |
| clinicaltrials |
| NCT06531291 | Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation | not yet recruiting | Phase 2 | 80 | RenJi HospitalOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06512467 | Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | Jul 22, 2024 | clinicaltrials |
| NCT06502080 | Consolidative Radiotherapy (CSRT) in Patients With Oligometastatic/Locally Advanced Unresectable Bilary Tract Cancer (BTC)(RADITOP) | not yet recruiting | Phase 2 | 128 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT06496815 | Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy | not yet recruiting | Phase 4 | 32 | Tongji HospitalOTHER | 0 | Jul 11, 2024 | clinicaltrials |
| NCT06490198 | Phase 2 Study: OBI-833/OBI-821 Maintenance for Globo H+ Advanced Biliary Tract Cancer After Gemcitabine/Cisplatin | not yet recruiting | Phase 1 | 30 | Chang Gung Memorial HospitalOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06463548 | Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma | not yet recruiting | N/A | 30 | Yunpeng LiuOTHER | 1 | Jun 18, 2024 | clinicaltrials |
| NCT06449846 | Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma | not yet recruiting | — | 152 | Zhujiang HospitalOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT06409637 | FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver Transplantation | not yet recruiting | Phase 1 / Phase 2 | 62 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT06089369 | Postoperative Adjuvant Sintilimab in Hepatocellular Carcinoma With Microvascular Invasion | not yet recruiting | Phase 3 | 360 | Tongji HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06389500 | HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer | not yet recruiting | Phase 2 | 30 | Harbin Medical UniversityOTHER | 0 | Apr 29, 2024 | clinicaltrials |
| NCT06375317 | HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure | not yet recruiting | Phase 2 | 42 | Yehua ShenOTHER | 0 | Apr 19, 2024 | clinicaltrials |
| NCT06369896 | Digital Single-operator Cholangioscopy and Intraductal Ultrasound for Nonicteric Biliary Strictures(Spy+IDUS) | not yet recruiting | — | 36 | Soonchunhyang University HospitalOTHER | 0 | Apr 17, 2024 | clinicaltrials |
| NCT06364787 | Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma | not yet recruiting | Phase 1 | 18 | Beijing 302 HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT06364800 | Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody | not yet recruiting | Early Phase 1 | 18 | Beijing 302 HospitalOTHER | 0 | Apr 15, 2024 | clinicaltrials |
| NCT06331260 | Assessment of AFP and PIVKA-II as Prognostic Indicators in Liver Transplantation for Hepatocellular Carcinoma | not yet recruiting | — | 600 | Zhejiang UniversityOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT06331273 | Impact of "No-touch" Technique on the Outcome of Liver Transplantation for Hepatocellular Carcinoma | not yet recruiting | — | 800 | Zhejiang UniversityOTHER | 0 | Mar 26, 2024 | clinicaltrials |
| NCT06317896 | Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS | not yet recruiting | — | 82 | Zhujiang HospitalOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT06311916 | Efficacy and Safety of Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model. | not yet recruiting | Phase 4 | 312 | Chen XiaopingOTHER | 0 | Mar 15, 2024 | clinicaltrials |
| NCT06313554 | Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma | not yet recruiting | N/A | 63 | Fudan UniversityOTHER | 0 | Mar 15, 2024 | clinicaltrials |
| NCT06253598 | Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 30 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 0 | Mar 7, 2024 | clinicaltrials |
| NCT06276153 | Construction of Multicenter Retrospective Registry Cohort Database for Gallbladder Cancer(CRGGCext) | not yet recruiting | — | 5,000 | RenJi HospitalOTHER | 0 | Feb 28, 2024 | clinicaltrials |
| NCT06196775 | A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 36 | Harbin Medical UniversityOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06178939 | Effects of Cognitive Intervention Therapy on Postoperative Delirium | not yet recruiting | N/A | 60 | Yonsei UniversityOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT06060847 | Liver Resection and Simultaneous Sleeve Gastrectomy for MS-HCC (LIRESS)(LIRESS) | not yet recruiting | N/A | 50 | Ospedale V. FazziOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT06173726 | Investigator-initiated Phase I Exploratory Clinical Study of the Safety, Tolerability, and Efficacy of BST02 Injection in the Treatment of Locally Advanced/Metastatic Liver Cancer | not yet recruiting | Early Phase 1 | 6 | BioSyngen Pte LtdINDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT06168357 | Role of Abbreviated MRI in Follow-up of Hepatocellular Carcinoma . | not yet recruiting | — | 55 | Assiut UniversityOTHER | 0 | Dec 13, 2023 | clinicaltrials |
| NCT05942560 | Effects of CBT-Based Intervention Among Patients With Liver Cancer | not yet recruiting | N/A | 160 | The Nethersole School of NursingOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05951231 | Liver Transplantation After ex Vivo Liver Perfusion(EVOLVE) | not yet recruiting | N/A | 22 | Oslo University HospitalOTHER | 0 | Nov 1, 2023 | clinicaltrials |
| NCT06089382 | A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection | not yet recruiting | Phase 3 | 104 | Tongji HospitalOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05976568 | A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 / Phase 3 | 668 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 4, 2023 | clinicaltrials |
| NCT05971628 | Resection And Partial LIver Transplantation With Delayed Hepatectomy for Hepatocellular Carcinoma(RAPID-HCC) | not yet recruiting | N/A | 50 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Aug 2, 2023 | clinicaltrials |
| NCT05897138 | A Study to Evaluate Lenvatinib Plus Tislelizumab for Locally Advanced Unresectable or Metastatic Hepatocellular Carcinoma With Hepatitis B Virus Infection and Biomarker Analyses | not yet recruiting | Phase 2 | 30 | Fujian Cancer HospitalOTHER_GOV | 0 | Jun 13, 2023 | clinicaltrials |
| NCT05896956 | The Construction of Clinical Database and Multiomics Biobank Based on a Multicentral Prospective Cohort of Benign and Malignant Biliary Tract Diseases | not yet recruiting | — | 500 | RenJi HospitalOTHER | 0 | Jun 9, 2023 | clinicaltrials |
| NCT05887505 | Effects of Vitamin D Status and Multiple Mega-dose Supplementation on Health Care Disparities in Perioperative Patients With Hepatocellular Carcinoma Receiving Hepatectomy | not yet recruiting | N/A | 120 | Taoyuan General HospitalOTHER_GOV | 0 | Jun 6, 2023 | clinicaltrials |
| NCT05752890 | A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma | not yet recruiting | — | 95 | National Taiwan University HospitalOTHER | 0 | Mar 3, 2023 | clinicaltrials |
| NCT05286320 | Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis. | not yet recruiting | Phase 1 / Phase 2 | 27 | National Taiwan University HospitalOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT05602974 | Adjuvant Stereotactic Body Radiotherapy (SBRT) for Hepatocellular Carcinoma After Hepatectomy With Narrow Margin: a Prospective, Multi-center, Randomized Controlled, Open-labelled, Phase III Study | not yet recruiting | N/A | 140 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 17, 2023 | clinicaltrials |
| NCT05718232 | SBRT Plus Lenvatinib and TACE for Advanced Primary HCC: A Phase 3 Trial (SEARCH)(SEARCH) | not yet recruiting | Phase 3 | 136 | Sun Yat-sen UniversityOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05644743 | Clinical Transformation of Organoid Model to Predict the Efficacy of GC in the Treatment of Intrahepatic Cholangiocarcinoma | not yet recruiting | — | 40 | Chengjun Sui,MDOTHER | 0 | Dec 9, 2022 | clinicaltrials |
| NCT04824742 | Neoadjuvant PDT in the Treatment of Cholangiocarcinoma | not yet recruiting | N/A | 50 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04053231 | Hepatocarcinoma Recurrence on the Liver Study - Part2(HERCOLES2) | not yet recruiting | — | 3,000 | University of Milano BicoccaOTHER | 1 | Aug 12, 2019 | clinicaltrials |
| NCT02785380 | Laparoscopic Surgery VS RFA for Recurrent HCC | not yet recruiting | Phase 4 | 340 | Sun Yat-sen UniversityOTHER | 0 | Jun 2, 2016 | clinicaltrials |
| NCT02779465 | Oral Vitamin D Treatment for the Prevention of Hepatocellular Carcinoma(VDHCC) | not yet recruiting | Phase 4 | 1,500 | Third Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | May 20, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Aug 2, 2024source: clinicaltrials